Safety and Pharmacokinetic Profile of CKD-581

Inclusion Criteria: * 20 years and older * Histologically or cytologically confirmed Lymphoma or Multiple myeloma that have failed to standard therapy or for which no life prolonging treatment exists * ECOG(Eastern cooperative oncology) performance status ≤ 2 * Life expectancy 12 weeks * Hematopoietic: ANC(Absolute Neutrophil Count) ≥ 1,500/mm3, Platelet count(PLT) ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL * Hepatic: Total bilirubin \> 1.5×upper limit of normal(except Gilbert's syndrome patients), aspartate aminotransferase(AST) \> 3×upper limit of normal, alanine aminotransferase(ALT) \> 3×upper limit of normal(AST, ALT ≤ 5.0×ULN in case of liver metastases) * Renal: serum creatinine ≤ 1.5×upper limit of normal * Serum calcium ≤ upper limit of normal (If the Multiple myeloma only) * Signed a written informed consent Exclusion Criteria: * Have symptoms with Brain metastases * History of Ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or Clinically significant heart disease such as NYHA Class III and IV Congestive atrial arrhythmias, within 6 months prior to first dose of study drug * Acute infection or blooding tendencies that would preclude study compliance * Other psychiatric disorders or other conditions that would preclude study compliance * Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks for radiation therapy) * Other concurrent antitumor therapy * Have Cardiac disease by nature * Administration history of Histone Deacetylase Inhibitor * History of Serious hypersensitivity or allergy * Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective contraception * Participation in a clinical trial within 4 weeks of first dose of study drug